Tuesday, September 22, 2009

US patent grant extends VivaGel coverage to 2024

22 September 2009 – Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) today announced that it has received notification of the grant in the US of a key patent specifically relating to the use of SPL7013 to protect against sexually transmitted infections (STIs).

The details can be read here.

No comments: